Advancements in HER2-Directed Therapy for Breast Cancer



 

HER2-positive metastatic breast cancer survival has improved significantly with many novel directed therapies under investigation. HER2-low expression can respond to directed therapy; however, more accurate testing is still needed.

Originally published on August 6, 2024


Lecture Presenter

Mei Wei, MD

Mei Wei, MD

Assistant Professor (Clinical) of Internal Medicine
Huntsman Cancer Institute at the University of Utah
Medical Oncologist, Internal Medicine
Huntsman Cancer Institute

Dr. Mei Wei is a medical oncologist and assistant professor (clinical) at the Huntsman Cancer Institute, University of Utah. Dr. Wei received her medical degree from Anhui Medical University. She completed residencies in gynecological oncology and radiation oncology Sun Yat-sen University Cancer Center, a postdoctoral research fellowship in cancer epidemiology at the University of Utah School of Medicine, an internship in internal medicine at the University of Nevada, Reno School of Medicine, a residency in internal medicine at the University of Utah School of Medicine, and a fellowship in hematology/oncology at the University of Utah School of Medicine. Dr. Wei focuses her practice on breast oncology with clinical research interests in clinical trials and breast cancer outcomes.


Objectives

After this presentation, participants will be able to:

  • Review the evolution of HER2-directed therapy for HER2-positive metastatic breast cancer
  • Review the definition, distribution of HER2-low breast cancer
  • Review the clinical significance of HER2-low expression among breast cancer
  • Review the challenges of HER2 testing

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories